Fig. 1.

Analyses of effectiveness by comorbidity (patients with/without CLD and patients with/without psychiatric comorbidity) at baseline: a  ≥ 50% seizure reduction (mFAS), b seizure freedom (FAS), c continuous seizure freedom (FAS), and d BRV retention (FAS). n represents the number of patients with data for the reported variable at each visit. Patients with missing data were excluded from all seizure analyses. Patients with missing data after BRV discontinuation were considered non-responders and not seizure free. BRV brivaracetam, CLD cognitive/learning disability, FAS full analysis set, mFAS modified full analysis set